Ionis Pharmaceuticals (IONS) Revenue (2009 - 2026)

Ionis Pharmaceuticals has reported Revenue for 18 years, with the latest figure at $246.1 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 86.98% year-over-year to $246.1 million; the trailing twelve-month figure through Mar 2026 stood at $608.1 million (down 15.21% YoY), and the FY2025 full-year result was $943.7 million, up 33.83% from the prior year.
• Revenue for Q1 2026 stood at $246.1 million, up from $203.3 million in the prior quarter.
• The five-year high for Revenue was $324.5 million in Q4 2023, with the low at $2.0 million in Q2 2025.
• Average Revenue over 5 years is $165.9 million, with a median of $151.9 million recorded in 2022.
• Year-over-year, Revenue surged 113.64% in 2023 and slumped 99.11% in 2025.
• Tracing IONS's Revenue over 5 years: stood at $151.9 million in 2022, then jumped by 113.64% to $324.5 million in 2023, then sank by 30.18% to $226.6 million in 2024, then fell by 10.26% to $203.3 million in 2025, then climbed by 21.03% to $246.1 million in 2026.
• The last three Revenue figures came in at $246.1 million (Q1 2026), $203.3 million (Q4 2025), and $156.7 million (Q3 2025), per Business Quant data.

Peer Comparison